Montirelin is a synthetic thyrotropin-releasing hormone (TRH) analog designed for research into mechanisms of consciousness and neuroactivation. In experimental models, it demonstrates potent analeptic activity, shortening the latency to recovery of the righting reflex at doses as low as 0.03 mg/kg, and is reported to be 30 to 100 times more potent than native TRH in reversing pentobarbital-induced narcosis. The compound acts by activating brain dopamine, noradrenaline, and acetylcholine neurons without directly binding to their respective receptors, and also restores suppressed EEG activity in ischemia models at doses above 0.003 mg/kg. This profile makes Montirelin a valuable tool for studying arousal, neuropeptide signaling, and neurotransmitter system interactions in preclinical research.

NS 3, Montirelinum, CNK-603, CNK 602A